Injectable Estradiol Dosing Regimens in Transgender and Nonbinary Adults Listed as Male at Birth.

Maralee Kanin, Margaret Slack, Reema Patel, Kuan-Ting Chen, Nicholas Jackson, Kristen C Williams, Shira Grock

Abstract read

In one paragraph

Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maralee KaninDivision of Endocrinology, Diabetes & Metabolism, University of California, Los Angeles, 10833 Le Conte Ave, 57-145 CHS, Los Angeles, CA 90095, USA.ORCID https://orcid.org/0009-0002-2025-3761

Margaret SlackDepartment of Medicine, Internal Medicine Residency, University of California, Los Angeles, 757 Westwood Plaza, Suite #7236, Los Angeles, CA 90095, USA.ORCID https://orcid.org/0009-0004-5185-6957

Reema PatelDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA.

Kuan-Ting ChenDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, 911 Broxton Ave, 3rd floor, Los Angeles, CA 90095, USA.

Nicholas JacksonDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, 911 Broxton Ave, 3rd floor, Los Angeles, CA 90095, USA.

Kristen C WilliamsDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue Box 951738, Los Angeles, CA 90095, USA.

Shira GrockDivision of Endocrinology, Diabetes & Metabolism, University of California, Los Angeles, 10833 Le Conte Ave, 57-145 CHS, Los Angeles, CA 90095, USA.ORCID https://orcid.org/0000-0002-9341-491X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Many transgender and nonbinary (TGNB) individuals assigned male at birth (AMAB) seek hormone therapy to achieve physical and emotional changes. Standard therapy includes estradiol, with or without an antiandrogen. Our clinical observations suggest that currently recommended injectable estradiol dosing may lead to supratherapeutic estradiol levels. Objective: We sought to evaluate whether lower-than-recommended doses of injectable estradiol were effective in achieving serum estradiol and testosterone goals. Methods: We conducted a retrospective cohort study to evaluate injectable estradiol dosing in treatment-naive AMAB individuals initiating hormone therapy. Data from a single provider at an academic center from January 2017 to March 2023 were analyzed. A total of 29 patients were eligible for inclusion. The primary variables of estradiol dosage, serum estradiol, and testosterone levels were analyzed over 15 months. Results: The average estradiol dose decreased from 4.3 to 3.7 mg weekly ( Conclusion: Lower doses of injectable estradiol can achieve therapeutic estradiol levels with excellent testosterone suppression. Spironolactone was not associated with additional testosterone suppression and may result in lower estradiol levels.

Indexed as

estradiol rangesinjectable estradioltransgender women

Identifiers

PMID40170698

DOI10.1210/jendso/bvaf004

PMCPMC11957913

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.